The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Proactive Investors interview:
"The company aims to develop a business case with York health economics group and Mid Yorkshire for broader NHS adoption, based on the successful outcomes and health economics work."
There are 195 NHS trusts, excluding Ambulance and Mental Health trusts, many with more than one site. If Steriwave is widely adopted after the preparation of the business case, the potential number of applications is considerable. There are also private hospitals to consider.
This extract is from the Ondine news update 25/03/24:
"SSIs are one of the most common healthcare-associated infections (HAIs) and affect one in every 20 patients who undergo a surgical procedure in the NHS. SSIs can cost up to £100,000 per patient, and the overall cost of HAIs to NHS England is over £2 billion a year. These costs are expected to rise as growing rates of antimicrobial resistance (AMR) make the current standard of care – the antibiotic mupirocin – less effective."
There is a massive opportunity for Ondine IMO.
Carol Cross CEO has take this from concept, thorough R&D and proving, trialled and accepted by surgeons and now on the cusp of large commercial rollout. At 62yrs of age and with her background and stature I am sure that she sees the best exit strategy is to sell to a big player who can scale up. The huge degree of success in reducing the need for antibiotics in post operative hospital care is evident and becoming globally 'viral' as surgeons and care teams communicate the savings. Steriwave is simple, quick, non-invasive and safe as it does not compromise the nasal biome weeks after the operation. A 75% reduction in the use of antibiotics to treat post op hospital acquired infections seems to be universal when Steriwave is used. That saves hospitals millions of pounds and thousands of days post op intervention and bed-blocking. It's a total no-brainer and just needs a major [probably US] Healthcare company to make her an offer and immediately scale it globally. As she holds 50% or so of the shares it would be a done deal. I mentioned 20p but I personally see it worth a lot more. Hopefully Carol Cross thinks likewise. I really cannot see any other direction than north from here.
Commercialised in Canada, yet no proof of revenues from these many hospitals
Hazbeen - the prouf in in the pudding
Adastra - do we expext to double like IMM?
RBC says target 60p
Given the raft of positive news now coming out from surgeons in all quarters of the profession, oropharyngeal, orthopaedics etc I have written to the company to request that they give possible financial projections of uptake. The recent NHS news must have huge potential and it would be great to see some meat on the bones.
Peter
Is it not already commercialised in Canada ?
It has already been approved
Commercialization is now the key focus at OBI
Carolyn Cross is 62, has steered Steriwave from concept, through R&D to commercialisation. It's now on the cusp of exponential adoption looking at success rates. Now is the time to put her exit strategy in play as she holds just under 50% of the shares in Ondine. Time to put it into play and watch the multiples scale it. The fact that a phase 3 trial in the USA is happening probably dictates where that bid will come from given the massive stateside potential. Just a matter of time and patience whilst this frustratingly low shareprice plays out.
Company now needs a major player to scale this breakthrough tech. The likes of Halma,Stryker,S&N could all quickly scale Steriwave now its gaining universal recognition and increased adoption. Consultants lead change and Steriwave is changing HAI post surgery. No brainer.
Obviously still loss making and cash flow negative
Reason more funding required
Last results minuscule revenues from the hospitals already using Stetiwave
Positive news - escalation of uptake - price falls. Bizarre.
So what revenues are being made from these deployments ?
Only a matter of time
Ross also highlighted Ondine's commercial momentum, including the deployment of Steriwave in eight new healthcare facilities and a growing international presence, now spanning 22 facilities in Canada and expanding in the UK and Spain.
The success is attributed partly to Steriwave's effectiveness in reducing the need for antibiotics, as demonstrated in a UK study, and its alignment with antimicrobial resistance efforts. Ondine plans to continue expanding in European markets, capitalize on its success in Canada, and explore potential in the United States through FDA phase three trials.
Ondine is a gamechanger. I invested in Immupharma in Jan/Feb and posted multiple reasons to buy at 1.3p. It has doubled in under a month. Ondine is similarly undervalued It's technology is cutting edge and is now snowballing after years of proof of concept and first-mover adoption.
Reducing antibiotic use is the single biggest driver in global Healthcare as we are unprepared for the next (inevitable) pandemic. Steriwave goes a long way to helping resolve Hospital acquired infections and it's multiple potential applications are being addressed. I can see many major companies being interested in picking up this tiddler before it flies above the radar.
"Surgical site infections are devastating. If you look at a surgical site infection in a total joint replacement, it’s a months-long recovery process,” says Dr. Andrew Glennie, a QEII orthopaedic surgeon and clinical champion for the Steriwave “test-and-try" in Canada.
Steriwave is currently trialing in NHS.
The 3 sell trades at 10p just before the close were my buys. Can someone explain how I was offered a price so different to the other buys that occurred around the same time.
If you are wondering why I made 3 trades: after the first trade, I decided it was worth buying more and then just before the close, I wondered if I could repeat my good fortune and since I could, I bought some more.
45 trades today. I think this share is still so under the radar it's unreal.
From X.....
Ondine Biomedical
@OndineBio
·
Mar 18
"It is a no-brainer for us and the nurses are very excited to be involved.”
Read about how the team at the #QEII Health Sciences Centre is using Ondine’s Steriwave technology. Special thanks to the
@QEIIFoundation
for funding this year-long study.
Ondine Biomedical Inc - Vancouver-based life sciences company - Announces significant commercial progress to date in 2024, ahead of management's expectations. Says Ondine's Steriwave technology is deploying in eight new healthcare facilities, including six new hospitals. This brings the total number of hospitals to 22, representing a 38% increase year-to-date and nearly quadruple the number a year ago. Two orthopedic surgeon group practices in the Toronto area will also shortly begin offering Steriwave to patients undergoing elective orthopedic procedures.
Current stock price: 9.64 pence, up 4.2% in London on Friday
I don't think that the true relevance of this contract has been evaluated by the investment community....yet.
NHS policy is used as a guide globally since it's decisions have major effects of its overall budget. This adoption of Steriwave after evaluation of a 6 month pilot was after a stringent cost/benefit analysis by one of its senior assessment authorities. The big point is that it's being used in orthopaedic pre-op which is a field change from the recent 77% reduction in HAI's in London oropharyngeal surgery.
Hi
Singer Capital Markets has today issued a short Company Update for OBI, which is a client. It describes the RNS as " very positive" on " a positive development" for the company. Singer has yet to revise its forecasts, recalculate its target price, or change its recommendation from "Buy".
Please note that Singer has yet to adjust OBI's number of shares in issue following the previous fundraise, and occasionally expresses figures actually in Sterling as CAD. In the absence of any estimate of the value for the NHS contract in Pontefract, Singer's Target Price should perhaps be treated as 56p, simply to take account of the 14% correction to the number of shares in issue (226mn versus 195mn).
let's hope that drives the SP up a tad more aggressively than we have seen so far.
Almas
BRIEF – Ondine Biomedical Says First Commercial Adoption Of Steriwave By NHS
07:57
March 25 (Reuters) – Ondine Biomedical Inc :
First Commercial Adoption Of Steriwave By Nhs
Source text for Eikon: ... Further company coverage:
(Reuters.Briefs@thomsonreuters.com;;)
Copyright 2024 Thomson Reuters. Click for restrictions.